Ovarian cyst - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Confirm the nature of the ovarian cyst (functional, benign, borderline, or malignant)

₹675₹1,500

55% OFF

Ovarian Cyst - Large Biopsy 3-6 cm: Comprehensive Medical Test Information Guide

Section 1: Why is it done?
- Test Purpose: This is a tissue sampling procedure used to obtain cells from ovarian cysts measuring 3-6 cm in diameter for histopathological examination to determine the benign or malignant nature of the lesion.
- Primary Indications: Detection of malignancy in complex or suspicious ovarian cysts; Differentiation between benign and malignant ovarian lesions; Evaluation of cysts with irregular borders or internal septations; Assessment of cysts with elevated tumor markers (CA-125, HE4); Investigation of cysts with concerning ultrasound or imaging features
- Typical Timing/Circumstances: Performed when imaging studies (ultrasound, CT, MRI) demonstrate intermediate-risk ovarian cysts; When cyst characteristics are ambiguous or concerning for malignancy; In postmenopausal women with newly discovered ovarian cysts; As part of preoperative workup before planned cyst removal; When clinical suspicion for ovarian cancer is moderate to high
Section 2: Normal Range
- Normal/Reference Values: Benign pathology findings (normal cytology); Absence of malignant cells or atypia; Cyst classification as simple serous cyst, follicular cyst, corpus luteum cyst, or other benign entities
- How to Interpret Results: Negative/Benign: No malignant cells present; tissue shows characteristic benign features; Positive/Malignant: Presence of malignant cells indicating ovarian cancer or other malignancy; Borderline: Atypical cells present with uncertain malignant potential; requires clinical correlation; Non-diagnostic: Insufficient cellular material for definitive interpretation; repeat biopsy may be recommended
- Units of Measurement: Qualitative histological diagnosis; Histological classification based on World Health Organization (WHO) criteria; Immunohistochemical staining results when applicable
- Normal vs. Abnormal Meaning: Normal findings indicate a benign cyst not requiring aggressive treatment; Abnormal findings suggest malignancy requiring immediate medical and surgical intervention; Results guide treatment decisions ranging from observation to chemotherapy and surgical removal
Section 3: Interpretation
- Benign Findings: Simple serous cystadenoma - fluid-filled structure with single cell layer lining; Follicular or corpus luteum cyst - normal physiologic cyst related to ovulation; Teratoma or dermoid cyst - benign germ cell tumor containing various tissue types; Fibromas or thecomas - benign stromal tumors; No epithelial atypia or malignant features present
- Malignant Findings: Serous cystadenocarcinoma - malignant epithelial ovarian cancer; Mucinous cystadenocarcinoma - mucinous epithelial malignancy; Clear cell carcinoma - high-grade malignant lesion; Endometrioid carcinoma - endometrium-like malignant tumor; Presence of cellular atypia, increased mitotic activity, and invasion
- Borderline/Atypical Findings: Borderline ovarian tumors (BOT) - intermediate category with uncertain malignant potential; Presence of nuclear atypia without stromal invasion; Requires careful clinical correlation and often close follow-up imaging
- Factors Affecting Interpretation: Specimen adequacy and cellularity; Previous biopsy or surgical history; Patient age and menopausal status; Associated tumor markers (CA-125, HE4, CEA) levels; Imaging characteristics and imaging modality used; Family history of ovarian cancer
- Clinical Significance of Result Patterns: Benign results typically permit conservative management or simple surgical removal; Malignant results necessitate staging studies and referral to gynecologic oncology; Borderline results may require repeat imaging or biopsy to clarify diagnosis; Grade and stage of any malignancy determine chemotherapy regimens and prognosis
Section 4: Associated Organs
- Primary Organ System: Female reproductive system (ovaries); Specifically the epithelial and germ cell components of ovarian tissue
- Associated Medical Conditions: Epithelial ovarian cancer (serous, mucinous, clear cell, endometrioid subtypes); Germ cell tumors (teratomas, dysgerminomas); Sex cord-stromal tumors (granulosa cell tumors, Sertoli-Leydig cell tumors); Polycystic ovary syndrome (PCOS); Ovarian endometriosis; Hereditary ovarian cancer syndromes (BRCA1/BRCA2 mutations)
- Diseases Diagnosed or Monitored: Primary ovarian malignancies; Metastatic cancers to the ovary; Ovarian cancer recurrence; Differentiation of primary ovarian cancers from secondary metastatic disease; Assessment of tumor grade and stage for prognostic purposes
- Potential Complications/Risks: Hemorrhage or bleeding from biopsy site; Infection or peritonitis; Cyst rupture with spillage of cyst contents; Ovarian torsion; Needle tract seeding of malignant cells (rare but theoretical risk); Damage to adjacent organs (bowel, bladder, blood vessels); Incomplete staging if cyst contains malignancy; Ovarian failure if extensive tissue damage occurs
Section 5: Follow-up Tests
- Additional Tests for Malignant Results: Computed tomography (CT) of abdomen and pelvis for staging; Positron emission tomography (PET-CT) for metastatic disease detection; Magnetic resonance imaging (MRI) for further tissue characterization; Tumor markers: CA-125, HE4, CEA, AFP; Complete blood count (CBC) and comprehensive metabolic panel; Chest X-ray or chest CT for pulmonary involvement screening
- Further Investigations if Indicated: Genetic testing (BRCA1/BRCA2) for hereditary cancer syndromes; Immunohistochemical staining for specific tumor markers; Flow cytometry for certain tumor types; Molecular testing for specific genetic mutations; Repeat biopsy if initial specimen is non-diagnostic
- Monitoring Frequency for Benign Results: Pelvic ultrasound every 3-6 months if cyst remains in situ; Annual gynecologic examination with imaging; Tumor marker monitoring if initially elevated; Imaging surveillance based on cyst characteristics and clinical judgment
- Monitoring Frequency for Malignant Results: Frequent imaging and tumor markers during chemotherapy (every 2-4 weeks); Post-operative imaging at 6-8 weeks following surgery; Regular follow-up imaging every 3-4 months for first 2 years; Extended surveillance intervals (every 6-12 months) beyond 2 years if in remission; Continuous monitoring for recurrence during entire surveillance period
- Complementary Tests: Pelvic ultrasound - initial imaging evaluation; Transvaginal ultrasound - improved visualization of ovarian pathology; Doppler ultrasound - assessment of vascular flow in cyst; Preoperative assessment of surgical candidacy; Postoperative imaging to assess treatment response
Section 6: Fasting Required?
- Fasting Requirement: YES - Fasting is typically required for 6-8 hours prior to the procedure
- Specific Fasting Instructions: NPO (nothing by mouth) from midnight the night before if procedure scheduled in morning; Clear liquids only until 2 hours before procedure if afternoon appointment; No solid food for minimum 6 hours before biopsy; Small amounts of water permitted up to 2 hours before procedure
- Medications to Avoid: Anticoagulants (warfarin, DOACs) - discontinue 3-5 days prior to procedure; Aspirin and NSAIDs - discontinue 5-7 days before procedure; Antiplatelet agents - coordinate timing with prescribing physician; Antibiotic prophylaxis may be required depending on risk factors
- Other Patient Preparation Requirements: Informed consent required with discussion of risks and benefits; Pregnancy test if applicable (women of childbearing age); Blood work: CBC, coagulation studies (PT/INR, PTT), blood type and crossmatch if surgery anticipated; Remove all jewelry, prosthetics, and metal objects; Wear loose, comfortable clothing for easy access to abdomen/pelvis; Arrange transportation as sedation may be used during procedure; Void bladder immediately before procedure; Identify allergies (especially to contrast media or anesthetics); Report all current medications to proceduralist; Discuss timing of procedure relative to menstrual cycle if applicable
- Post-Procedure Considerations: Resume normal diet after procedure as tolerated; Pain management with prescribed analgesics; Pelvic rest for 2-3 days following biopsy; Monitor for fever, heavy bleeding, or severe pain; Follow specific instructions provided by interventional radiologist or surgeon; Schedule follow-up appointment to discuss results

How our test process works!